Variables | YORA (N= 475) | LORA (N= 75) | P-value |
---|---|---|---|
Age at onset, yr | <58 | ≥58 |  |
Female, n (%) | 357/475 (75.2) | 292/475 (61.5) | Â |
Disease duration (mo) | 6.90 (3.42) | 6.45 (3.20) | <0.05 |
RF+, n (%) | 354/466 (75.9) | 349/468 (75.6) | NS |
ANA+, n (%) | 91/377 (24.2) | 69/352 (19.6) | NS |
ACPA+ n (%) | 313/429 (72.9) | 267/411 (64.9) | <0.05 |
PTPN22 T variant, n (%) | 155/405 (38.3) | 106/381 (27.8) | <0.01 |
HLA-SE, shared epitope, n (%) | 237/405 (58.5) | 219/381 (57.5) | NS |
ESR at T0, mm/h (n = 948) | 26.0 (21.5) | 34.3 (24.2) | <0,001 |
CRP at T0 mg/L (n = 888) | 18.3 (23.7) | 23.0 (24.6) | <0.01 |
DAS28 at T0, (n = 788) | 4.5 (1.5) | 4.8 (1.4) | <0.01 |
AUC DAS28 (6 mo)b | 24.5 (7.2) | 25.9 (7.0) | <0.01 |
AUC DAS28 (12 mo)b | 44.8 (13.4) | 47.7 (13.2) | <0.01 |
AUC DAS28 (24 mo)b | 84.2 (26.8) | 89.0 (23.3) | <0.05 |
HAQ at T0, (n = 796) | 0.81 (0.6) | 0.92 (0.6) | <0.01 |
Tender joints at T0 (n = 811) | 6.3 (5.6) | 6.5 (5.7) | NS |
Swollen joints at T0, (n = 812) | 6.8 (5.2) | 7.3 (5.2) | NS |
VAS pain at T0 (mm), (n = 800) | 43.5 (25.5) | 43.4 (25.9) | NS |
VAS global at T0 (mm) (n = 800) | 44.0 (25.8) | 45.0 (25.5) | NS |
Smoker (ever) T0, n (%) | 287/443 (64.8) | 300/447 (67.1) | NS |
Ex-RA ≤ T5, n (%)c,d | 13/344 (3.8) | 14/313 (4.5) | NS |
Nodules ≤ T5, n (%)c | 60/312 (19.2) | 38/275 (13.8) | 0.079 |
DMARDs within 3 mo after T0, n (%)c,e | 325/346 (93.9) | 267/311 (85.9) | <0.001 |
DMARDs (ever) ≤T5, n (%)c | 344/348 (98.9) | 299/310 (96.5) | <0.05 |
Methotrexate (ever) ≤T5, n (%)c | 313/346 (90.5) | 253/311 (81.4) | <0.001 |
Biologics (ever) ≤T5, n (%)c | 84/342 (24.6) | 23/310 (7.4) | <0.001 |
NSAID T0, n (%) | 317/455 (69.7) | 297/466 (63.7) | 0.056 |
NSAID ever ≤T5, n (%)c | 307/340 (90.3) | 233/307 (75.9) | <0.001 |
COX-2-inhibitors at T0, n (%) | 48/459 (10.5) | 64/468 (13.7) | NS |
COX-2-inhibitors (ever) ≤T5, n (%)c | 95/342 (27.8) | 83/309 (26.8) | NS |
Corticosteroids T0 to T5 (mo)c | 20.3 (23.8) | 24.7 (23.8) | <0.01 |
Corticosteroids (ever) ≤T5 (%)c | 230/346 (66.5) | 233/309 (75.4) | <0.01 |
Hypertension at T0, n (%) | 56/471 (11.9) | 199/474 (41.9) | <0.001 |
DM at T0, n (%) | 22/464 (4.7) | 54/470 (11.5) | <0.001 |
CVD before T0, n (%)f | 17/471 (3.6) | 93/474 (19.6) | <0.001 |
CVD related comorbidity at T0, n (%)g | 86/475 (18.1) | 238/475 (50.1) | <0.001 |
Larsen score 0 (mo) (n = 437) | 5.3 (5.8) | 8.5 (6.2) | <0.001 |
Larsen score 24 (mo) (n = 381) | 9.5 (9.1) | 12.5 (8.2) | <0.001 |
Erosions 0 mo, n (%) | 85/212 (40.1) | 105/192 (54.7) | <0.01 |
Erosions 24 mo, n (%) | 107/173 (61.8) | 119/158 (75.3) | <0.01 |
Δ Larsen score 0 to 24 mo ≥3, n (%) | 103/207 ( 49.8) | 97/173 ( 56.1) | 0.131 |